PBT down 11.4% and operating cash down 39% despite 9.1% revenue growth

What changed

Revenue rose 9.1% to NZ$441.5m, but profit before tax fell 11.4% to NZ$25.2m. Reported NPAT was essentially flat at NZ$18.8m (+0.6%), propped up by a lower effective tax rate (25.4% vs 34.3%) and a small positive contribution from a discontinued operation — continuing-operations profit was NZ$17.6m, down from NZ$19.3m. Operating cash inflow dropped 39.4% to NZ$59.8m from NZ$98.6m. Total assets grew 12.7% to NZ$904.2m while total equity fell 9.2% to NZ$317.5m. The announced final dividend of 4.0cps is up 60% on the prior final of 2.5cps (FY21 full-year dividends totalled 5.0cps, so full-year comparability is not available from this release).

What matters

• Operating earnings weakened even as revenue grew. PBT is the cleaner read here, and it fell 11.4% on a 9.1% revenue increase, implying underwriting or claims pressure absorbed the premium growth. The flat NPAT is a tax and classification artefact, not operational improvement.
• Cash conversion deteriorated materially. Operating cash fell NZ$38.9m year on year, a far steeper move than the NPAT line would suggest. With the extracted cash balance reading only NZ$0.084m versus NZ$116.1m prior, there is either a meaningful rundown of on-balance-sheet liquidity or an OCR error in the source; either way, the liquidity position cannot be confirmed from this packet.
• Capital return was lifted despite weaker operating results. The final dividend rose 60% against falling PBT, falling equity (–9.2%), and a 39% drop in operating cash — a notable disconnect between capital allocation and underlying earnings direction.

Expectations

No FY23 forward guidance or stated target is provided in the supplied FY22 release. Prior HY22 materials referenced an underlying NPAT guidance range of NZ$21–25m excluding large events, but no reconciliation or restatement of underlying NPAT for FY22 is in the supplied excerpts, so the result cannot be benchmarked against that range from this packet. The shape context is stark: HY22 NPAT was only NZ$2.9m (15.6% of full-year), implying a ~NZ$15.9m second-half NPAT. The FY22 outcome is therefore heavily dependent on a strong second half rather than an even run-rate, which raises the bar for what a "normal" FY23 should look like.

Quality of result

Low durability. The flat NPAT is flattered by:

• An effective tax rate that fell roughly 9 percentage points at the bottom line, partly reflecting a discontinued-operation contribution — continuing-operations tax burden is closer to 30%.
• A second-half skew that delivered an estimated NZ$15.9m of NPAT after only NZ$2.9m in the first half.
• The absence of a disclosed large-events adjustment in the statutory release, so the split between underlying and event-driven earnings cannot be verified here.

Set against a 39% drop in operating cash and falling equity, the underlying earnings signal is weaker than the headline.

Unresolved

• Actual FY22 cash and investments position, given the apparent NZ$0.084m figure is inconsistent with the rest of the balance sheet.
• The driver of the operating-cash decline — claims timing, reinsurance recoveries, premium receivables, or investment flows.
• FY22 segment mix (New Zealand vs Pacific Islands): prior year showed Pacific Islands delivering most of the group PAT on ~13% of revenue, so any shift materially changes the margin picture.
• Underlying NPAT excluding large events for FY22, and whether FY22 lands inside the HY22 guidance corridor.
• Solvency headroom relative to target, which was NZ$56.6m above target at FY21 but is not quantified in the supplied FY22 excerpts.
• Any FY23 guidance, capital-return plans beyond the final dividend, and reinsurance renewal terms.

This briefing cannot assess underlying (ex-large-events) earnings, solvency headroom, or segment-level performance for FY22, because those disclosures are not in the supplied extraction.

Key metrics

Segment breakdown

Analytical metrics

---

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.